Find Clinical Trials
Dose-response study of gevokizumab (S78989) 3mg, 10mg, 30mg or 60mg in patients with type 2 diabetes and diabetic kidney disease (DKD). A 66-week, international, multicenter, randomized, double-blind, parallel-group, placebo controlled study.
Servier Protocol Code:
CL2-78989-011
Sponsor:
Institut de Recherches Internationales Servier (I.R.I.S)
EudraCT Number:
2013-003610-41
Find a recruiting site
Name:
Institut de Recherches Internationales Servier, Département des études cliniques
Phone number:
+33 1 55 72 60 00
Results
English (USA)Interventions / Treatments
The treatment(s) given to the participants in the study.
- Diabetes - Type II
- GEVOKIZUMAB
- S078989
Other study id numbers
Other identification numbers the study may be known by.
- CL2-78989-011